Synthesis and aldose reductase inhibitory activity of some new chromonyl-2,4-thiazolidinediones

被引：37

作者：

Bozdak-Dundar, Oya ^{[1
]}

Evranos, Begiim ^{[1
]}

Das-Evcimen, Net ^{[2
]}

Sarikaya, Mutlu ^{[2
]}

Ertan, Rahmiye ^{[1
]}

机构：

[1] Ankara Univ, Fac Pharm, Dept Pharmaceut Chem, TR-06100 Ankara, Turkey

[2] Ankara Univ, Fac Pharm, Dept Biochem, TR-06100 Ankara, Turkey

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2008年 / 43卷 / 11期

关键词：

Chromone derivatives; 2,4-Thiazolidinediones; Chromonyl-2,4-thiazolidinediones; Aldose reductase; Aldose reductase inhibition; Synthesis;

D O I：

10.1016/j.ejmech.2008.01.004

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

As it is known that still, there were no any confident ARIs on the market and they have several side effects, we need to approve new ARIs to reduce diabetic complications especially which have effect on the cataract formation. In this study, a new series of chromonl-2,4-thiazolidinediones (Ia-e, IIa-e, IIIa-e) were prepared by Knoevenagel reaction with substituted 3-formylchromones (3a-e) and unsubstituted (1) or substituted 2,4-thiazolidinedione (2). The synthesized compounds were tested for their ability to inhibit rat kidney AR by an in vitro spectrophotometric assay. Compound IIIe showed the highest inhibitory activity (82.43 +/- 0.76%). Compounds la-e and IIIa-d also showed significant inhibitory activity (42.40 +/- 5.78, 52.71 +/- 3.31, 49.69 +/- 1.55, 50.80 +/- 3.62, 46.70 +/- 2.33, 49.44 +/- 4.53, 61.17 +/- 4.74, 68.58 +/- 2.05, 77.28 +/- 0.26%, respectively). (C) 2008 Elsevier Masson SAS. All rights reserved.

引用

页码：2412 / 2417

页数：6

共 31 条

[1]

Beecher GR, 2003, J NUTR, V133, p3248S

[2] INHIBITION-KINETICS OF HUMAN KIDNEY ALDOSE AND ALDEHYDE REDUCTASES BY ALDOSE REDUCTASE INHIBITORS [J].

BHATNAGAR, A ;

LIU, S ;

DAS, B ;

ANSARI, NH ;

SRIVASTAVA, SK .

BIOCHEMICAL PHARMACOLOGY, 1990, 39 (06) :1115-1124

[3]

BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3

[4] Aldose reductase inhibitor zopolrestat restores allergic hyporesponsiveness in alloxan-diabetic rats [J].

Carvalho, Vinicius F. ;

Barreto, Emiliano O. ;

Serra, Magda F. ;

Cordeiro, Renato S. B. ;

Martins, Marco A. ;

Fortes, Zuleica Bruno ;

Silva, Patricia M. R. e .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 549 (1-3) :173-178

[5] ANTIINFLAMMATORY AND ALDOSE REDUCTASE INHIBITORY ACTIVITY OF SOME TRICYCLIC ARYLACETIC ACIDS [J].

CERELLI, MJ ;

CURTIS, DL ;

DUNN, JP ;

NELSON, PH ;

PEAK, TM ;

WATERBURY, LD .

JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (11) :2347-2351

[6] Pharmacological approaches to the treatment of diabetic complications [J].

Costantino, L ;

Rastelli, G ;

Gamberini, MC ;

Barlocco, D .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (08) :1245-1262

[7] Aldose reductase inhibitors from natural sources [J].

de la Fuente, JA ;

Manzanaro, S .

NATURAL PRODUCT REPORTS, 2003, 20 (02) :243-251

[8]

DeLima M.C.A., 1992, PHARMAZIE, V47, P182

[9] Synthesis, activity, and molecular modeling of new 2,4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors [J].

Fresneau, P ;

Cussac, M ;

Morand, JM ;

Szymonski, B ;

Tranqui, D ;

Leclerc, G .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (24) :4706-4715

[10] EFFECT OF NEW ORAL ANTIDIABETIC AGENT CS-045 ON GLUCOSE-TOLERANCE AND INSULIN-SECRETION IN PATIENTS WITH NIDDM [J].

IWAMOTO, Y ;

KUZUYA, T ;

MATSUDA, A ;

AWATA, T ;

KUMAKURA, S ;

INOOKA, G ;

SHIRAISHI, I .

DIABETES CARE, 1991, 14 (11) :1083-1086

← 1 2 3 4 →